Could a common mineral ease rare genetic disorder? zinc trial shows promise

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * GNAO1 associated neurological disorder, documented by either * Proven pathogenic or likely pathogenic mutation in GNAO1 or * a variant of unknown significance in GNAO1 and clinical symptoms likely to be consistent with GNAO1 as determined by the investigators and * at least one of the common symptoms of GNAO1: Movement disorder (Dystonia, Chorea, Ataxia, clonic), central muscular hypotonia, epilepsy, global developmental delay * Age: 6 month - 30 years * GMFM ≤ 75 * written informed consent prior to any trial-related procedure (according to age and status of psycho-intellectual development) * of parents or legal guardian * of parents or legal guardian and patient * of the patient * stable on following concomitant treatments for at least 3 months prior to trial inclusion: anti-seizure drugs (ASD); baclofen, Deep brain stimulation settings Exclusion Criteria: * Treatment of Zinc in the last 4 months before inclusion * known other genetic variants that are known to cause symptoms like observed in GNAO1-related disorders, additional to the proven GNAO1 mutation * implantation of Deep brain stimulation planned during the duration of the trial, i.e. in the six months after inclusion * start of intrathecal baclofen therapy planned during the duration of the trial, i.e. in the six months after inclusion * Known allergy/hypersensitivity to the scheduled trial drug * Concomitant participation in other clinical drugs with investigational drugs or with competing interventions * sexually active patients who are not willing to use/ not using a highly effective contraception method with a pearl-index \< 1. Sexually active patients, unless surgically sterile, must be using a highly effective contraception method (including oral, transdermal, injectable or implanted contraceptives, intrauterine device (IUD), using a condom of the sexual partner or sterile sexual partner) and must agree to continue using such precautions during the whole study period. * Pregnant women and nursing mothers